KRCA-0008
CAS No. 1472795-20-2
KRCA-0008 ( KRCA 0008 | KRCA0008 )
产品货号. M12023 CAS No. 1472795-20-2
KRCA-0008 是一种有效的选择性 ALK 抑制剂,IC50 为 12 nM(wt ALK)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥245 | 有现货 |
|
| 5MG | ¥392 | 有现货 |
|
| 10MG | ¥550 | 有现货 |
|
| 25MG | ¥1079 | 有现货 |
|
| 50MG | ¥1851 | 有现货 |
|
| 100MG | ¥2961 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥525 | 有现货 |
|
生物学信息
-
产品名称KRCA-0008
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述KRCA-0008 是一种有效的选择性 ALK 抑制剂,IC50 为 12 nM(wt ALK)。
-
产品描述KRCA-0008 is a potent, selective ALK inhibitor with IC50 of 12 nM (wt ALK), also is potent against various ALK mutants, including L1196M, F1174L, R1275Q, and C1156Y (IC50=5-75 nM); weakly inhibits IR (IC50=210 nM), inhibits H3122 and BaF3 EML4-ALK L1196M cell proliferation with IC50 of 80 and 68 nM, respectively; demonstrates in vivo efficacy comparable to Crizotinib in xenograft mice model, has drug-like properties without hERG concerns.
-
体外实验Cell Proliferation Assay Cell Line:H3122 and H1993 cell lines Concentration:200 nM Incubation Time:6 hours Result:Inhibited cell proliferation of H3122 and H1993 cells with IC50s of 0.08 and 3.6 nM, respectively.Cell Proliferation Assay Cell Line:NPM-ALK-positive ALCL cell lines (Karpas-299 and SU-DHL-1) and U937 NPM ALK-negative lymphoma cell line Concentration:200 nM Incubation Time:72 hoursResult:Inhibited proliferation of Karpas-299, SU-DHL-1 and U937 cells with GI50s of 12 nM, 3 nM and 3.5 μM, respectively.Western Blot Analysis Cell Line:Karpas-299 and SU-DHL-1 cell lines Concentration:0, 10, 100 and 1000 nMIncubation Time:4 hoursResult:Completely suppressed phosphorylation of ALK and its effectors at a dose of 100 nM in NPM-ALK-positive ALCL cells.Apoptosis AnalysisCell Line:SU-DHL-1 cell line Concentration:0-1 μM Incubation Time:72 hours Result:Dose-dependently increased cspase-3/7 activities and induced cell apoptosis.Cell Cycle Analysis Cell Line:Karpas-299 and SU-DHL-1 cell lines Concentration:0-100 nM Incubation Time:48 hours Result:Induced G0/G1 cell cycle arrest in ALCL cells expressing NPM-ALK.
-
体内实验Animal Model:NOD/SCID mice with Karpas-299 xenograftsDosage:25 and 50 mg/kg Administration:Oral gavage; 25 and 50 mg/kg twice a day; for two weeks Result:Significantly inhibited tumor growth by inhibiting NPM-ALK phosphorylation without showing overt signs of toxicity or significant compound-related body weight loss.
-
同义词KRCA 0008 | KRCA0008
-
通路Angiogenesis
-
靶点ALK
-
受体ACK|ALK
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1472795-20-2
-
分子量609.119
-
分子式C30H37ClN8O4
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESClC1=CN=C(NC2=CC=C(N3CCN(C(C)=O)CC3)C=C2OC)N=C1NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC
-
化学全称Ethanone, 1,1'-[(5-chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bis-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Park CH, et al. Bioorg Med Chem Lett. 2013 Nov 15;23(22):6192-6.
2. Kang CH, et al. Biochem Biophys Res Commun. 2015 Aug 28;464(3):762-7.
3. Lee HJ, et al. Arch Pharm Res. 2014;37(9):1130-8.
产品手册
关联产品
-
GSK1838705A
GSK1838705A 是一种有效的 IGF-IR 和胰岛素受体 (IR) 特异性抑制剂,IC50 分别为 2.0 和 1.6 nM。
-
INCB-000928
Zilurgisertib (INCB-000928; NBU-928) 是一种选择性的 ALK 2 抑制剂,用于研究癌症等疾病。
-
Iruplinalkib
Iruplinalkib (WX-0593) 是一种有效的、选择性的、具有口服活性的 ALK 和 ROS1 酪氨酸激酶抑制剂。Iruplinalkib (WX-0593) 在伴有 ALK 或 ROS1 重排的晚期 NSCLC 中显示出良好的安全性和有希望的抗肿瘤活性。
021-51111890
购物车()
sales@molnova.cn

